What is it about?
Age-related macular degeneration (ARMDD) is the leading cause of irreversible vision loss, affecting one in three people aged 75 or older. While exciting new pharmaceuticals to treat ARMD as an endothelial growth factor (VEGF) inhibitors are now available, these are effective only in a select group of patients, and can be used only during a narrow time window. Monthly intravitreal anti-VEGF injections with systemic exposure to anti-VEGF will be replaced by new drugs taken in a non-invasive way. Statins are the most commonly used lipid lowering drugs. The objective of this review is to evaluate the evidence and discuss the rationale behind the recent suggestions that statins may be useful in the prevention and treatment of age-related macular degeneration.
Featured Image
Why is it important?
Age-related macular degeneration (ARMDD) is the leading cause of irreversible vision loss, affecting one in three people aged 75 or older. While exciting new pharmaceuticals to treat ARMD as an endothelial growth factor (VEGF) inhibitors are now available, these are effective only in a select group of patients, and can be used only during a narrow time window.
Perspectives
New intervention as statins usage to prevent the development of age-related macular degeneration and its progression remain an important strategy to limit the morbidity of this significant public health problem.
Prof., Dr Marianne M Shahsuvaryan
Yerevan State Medical University Named after Mkhitar Heratsi
Read the Original
This page is a summary of: Therapeutic Potential of Statins in Age-related Macular Degeneration, Sierra Leone Journal of Biomedical Research, November 2011, African Journals Online (AJOL),
DOI: 10.4314/sljbr.v3i2.71807.
You can read the full text:
Contributors
The following have contributed to this page
